11505 RESULTS
COMMENT This study is very interesting. A metabolite of the kynurenine pathway, kynurenic acid, is an antagonist of NMDA receptors, and so this pathway might also affect synaptic plasticity. stromeyerc_235326 0 The kynurenine pathway and the brain: Challenges, co
COMMENT These studies are fascinating for innovatively implicating glycolysis in the pathogenesis of AD as well as for drawing attention to the importance of astrocytes. Their implication of IDO-1 as a therapeutic regulator of this process is also interesting, id
COMMENT This is an impressive study by Minhas et al. that uses multiple orthogonal experimental approaches to dissect the mechanism by which the rate-limiting enzyme in the conversion of tryptophan to kynurenine, IDO1, regulates glycolysis in astrocytes, with dow
COMMENT Andreasson and colleagues have found, using both in vitro and in vivo models, that kynurenine (Kyn) generated by IDO1 suppresses glycolytic metabolism in astrocytes, therefore highlighting the therapeutic potential of IDO1 inhibitors for Alzheimer’s disea
COMMENT This study by Minhas et al. is outstanding in its rigor and significance for both Alzheimer’s disease (AD) and other neurodegenerative conditions. It provides a new mechanistic insight into the cause of AD, thereby facilitating potential new therapies, so
COMMENT I wonder if the observed effects of anti-Aβ therapy would be also produced by injection of control IγG. What comes to mind in this regard are these studies on the positive effect on dementia of various vaccination regimes. igork 0 Lower Risk for Dementia
COMMENT It is well known that the cortex swells slightly as Alzheimer’s disease develops (see for example recent work from Phan et al., 2024), probably due to reactive changes (gliosis, not inflammation) as the Aβ amyloid aggregates and deposits in the parenchyma
COMMENT This is a comprehensive study expanding current understanding of perineuronal nets in regulating synaptic structure and function. It must be said that the claim that “whether PNNs interact structurally and functionally with astrocytes at tripartite synaps
COMMENT I am surprised by such negativity. We all are looking for new avenues in developing new drugs beyond amyloid for treating AD and this path is littered with failures. Any new study that shows signs of improvement should be taken seriously, not discarded be
COMMENT This study combines data from a group of primary care practices and from the BioFINDER study to analyze the value of plasma %p-tau217 (measured as part of the C2N Precivity2 assay and compared against the p-tau217 percentage occupancy alone) in improving
COMMENT I share Dr. Jucker's skepticism for what is reported as being detected by the Aβ (OC+) antibody used. We have found several different antibodies to label similar clusters adjacent to the foot processes of GFAP-labeled astrocytes in older mice. We ha
COMMENT We are very pleased that our study uploaded on bioRxiv, on proteostasis as a fundamental principle of Tau immunotherapy, is now out in the journal Brain. j.goetz 0 Proteostasis as a fundamental principle of Tau immunotherapy.
COMMENT I think this is a fascinating and timely research article, demonstrating that the propagation of slow waves across the neocortex during sleep is impaired in older individuals. This impairment is correlated to the degree of tau tangle pathology in the brai
COMMENT This is an exciting resource and accompanying manuscript which demonstrates the critical importance of multiregional brain profiling to define molecular cellular phenotypes of brain disease. By sampling multiple regions at different stages of disease, the
COMMENT This study is a landmark in AD research because of its detailed cellular and molecular characterization of postmortem human brain samples. Previously, the same group published an snRNA-Seq database of hundreds of cases from one brain region. In this study
